Pulmonary infection with Cryptococcus neoformans in the face of underlying sarcoidosis

Respiration

Volumn 74, Issue 4, 2007, Pages 462-466

  Boyton, Rosemary J ^a,b,c   Altmann, Daniel M ^a   Wright, Andrew ^c   Kon, Onn Min ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

CD4 T cell; Cryptococcus neoformans; Immunotherapy; Sarcoidosis; Th1

Indexed keywords

CORTICOSTEROID; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BIOCHEMISTRY; CASE REPORT; CEREBROSPINAL FLUID CULTURE; COUGHING; CRYPTOCOCCUS NEOFORMANS; DYSPNEA; FEVER; FIBEROPTIC BRONCHOSCOPY; FORCED EXPIRATORY VOLUME; HISTOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG INFECTION; LUNG LAVAGE; LUNG VOLUME; MALE; NEUROLOGIC EXAMINATION; NIGHT SWEAT; PATHOGENICITY; PNEUMONIA; PRIORITY JOURNAL; SARCOIDOSIS; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; TRACHEOBRONCHITIS; TRANSBRONCHIAL BIOPSY; VIRULENCE; WEIGHT REDUCTION;

ADULT; ANTIFUNGAL AGENTS; BIOPSY; BRONCHOALVEOLAR LAVAGE; BRONCHOSCOPY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES, FUNGAL; MALE; SARCOIDOSIS, PULMONARY; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34548180858     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087461     Document Type: Article

References (12)

1. Rodrigues ML, Alviano CS, Travassos LR: Pathogenicity of Cryptococcus neoformans: Virulence factors and immunological mechanisms. Microbes Infect 1999;1:293-301.
2. Rogge L, Papi A, Presky DH, Biffi M, Minetti LJ, Miotto D, Agostini C, Semenzato G, Fabbri LM, Sinigaglia F: Antibodies to IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol 1999;162:3926-3932.
3. Boyton RJ, Openshaw PJ: Pulmonary defences to acute respiratory infection. Br Med Bulletin 2002;61:1-12.
4. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE: Practice guidelines for the management of cryptococcal disease . Clin Infect Dis 2000;30:710-718.
5. de Klerk AAG, Bezuidenhout J, Bolliger CT: A young healthy woman presenting with acute meningitis and a large pleural-based mass. Respiration 2003;70:655-657.
6. Buchanan KL, Murphy JW: What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 1998;4:71-82.
7. Currie BP, Freundlich LF, Casadevall A: Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol 1994;32:1188-1192.
8. Koguchi Y, Kawakami K: Cryptococcal infection and Th1-Th2 cytokine balance . Int Rev Immunol 2002;21:423-438.
9. Kawakami K, Koguchi Y, Qureshi MH, Miyazato A, Yara S, Kinjo Y, Iwakura Y, Takeda K, Akira S, Kurimoto M, Saito A: IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J Immunol 2000;165:941-947.
10. Kawakami K: Promising immunotherapies with Th1-related cytokines against infectious disease. J Infect Chemother 2003;9:201-209.
11. Bingisser R, Speich R, Zollinger A, Russi E, Frei K: Interleukin-10 secretion by alveolar macrophages and monocytes in sarcoidosis. Respiration 2000;67:280-286.
12. Humphreys IR, Edwards L, Walzl G, Rae AJ, Dougan G, Hill S, Hussell T: OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol 2003;170:6125-6132.